APR 09, 2020 4:36 PM PDT

Adjuvant immunotherapy proves effective for colon cancer

Results from a study published in Nature Medicine highlights the benefits of receiving pre-surgery immunotherapy for some types of colon cancer. The NICHE study was carried out by scientists at the Netherlands Cancer Institute and found that 100% of patients in a phase II clinical trial with MSI colon cancer benefited from immunotherapy pre-surgery, while 25% of MSS colon cancer patients saw benefits.

Pre-surgery immunotherapy, also known as neoadjuvant immunotherapy, is meant to keep cancer from metastasizing while also giving the immune system a head-start to recognize tumor variations. Ideally, this allows the immune system a better opportunity to respond once the tumor is removed by surgery.

While the researchers conducting the clinical trials hoped for positive results, they say they were blown away with their findings. 'A good response rate was on the cards in this group', says oncologist and project manager Myriam Chalabi. 'But a 100% rate is unprecedented. You don't dare hope it will be that good.'

Participating in the study were 40 patients with two different colon cancer subtypes: microsatellite-instable (MSI) tumors and microsatellite-stable (MSS) tumors. MSI means that the tumor is very susceptible to mutation; this subtype of colon cancer typically responds well to immunotherapy and the researchers showed that 100% of the patients responded well. MSS, on the other hand, does not typically respond well to immunotherapy; however, the researchers showed that 25% of the group responded well to adjuvant immunotherapy.

The researchers wanted to understand these unexpectedly positive results for MSS. “We looked at all the usual suspects, but they weren't the cause', says Chalabi. “We didn't see the same predictive factors as in melanoma, for instance. But in the end, we did find a new biomarker. If that proves to be predictive in follow-up studies, it could provide a simple way of identifying patients with MSS tumors who could benefit from immunotherapy.”

Photo: Pixabay

The researchers at the Netherlands Cancer Institute had previously shown in past studies that neoadjuvant immunotherapy has similar success outcomes for melanoma; they are simultaneously carrying out investigation on other types of tumors, as well. The researchers plan to continue monitoring the patients already involved in the colon cancer study for a minimum of three more years, in addition to increasing the number of patients involved. 'Only then can the new therapy be considered as a standard treatment', says Chalabi.

Sources: Nature Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 21, 2020
Cancer
MAR 21, 2020
Identifying aggressive prostate cancer subtypes
New research published yesterday in the British Journal of Cancer from scientists at the University of East Anglia descr ...
MAR 22, 2020
Cancer
MAR 22, 2020
What is "Shotgun ion mobility mass spectrometry sequencing"?
Research published recently in Nature Communications highlights a new method of mapping an essential family of polysacch ...
APR 07, 2020
Cancer
APR 07, 2020
Chemo drugs are leaking into our water
With cancer as the second leading cause of death globally, it comes as a surprise that we know very little up until now ...
APR 18, 2020
Cancer
APR 18, 2020
A New Double Threat Against Skin Cancer
Skin cancer is one of the most common cancers in America.  One of the most aggressive forms of cancer is melanoma, ...
MAY 07, 2020
Cell & Molecular Biology
MAY 07, 2020
How the Function of a Critical Immune Cell is Related to Metabolism
This work suggests that it may be possible to dampen autoimmunity or promote an immune attack on cancer through a bioche ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
Loading Comments...